Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Aberrant activation of the epidermal growth factor receptor (EGFR) is implicated in human cancer pathogenesis.
• Therapeutic anti-EGFR antibodies like cetuximab and matuzumab inhibit EGFR-expressing tumor cells.
• Enhancing EGFR-targeted therapies may involve inducing endogenous antibody responses.

Purpose of the Study:

• To identify novel peptide sequences that bind to anti-EGFR antibodies.
• To investigate if these peptides can induce an endogenous antibody response with anti-tumoral activity.

Main Methods:

• Selection of peptide sequences from random libraries for binding to single-chain antibody fragments of cetuximab and matuzumab.
• Characterization of peptide motifs (KTL and YPLG) recognized by both antibodies.
• Immunization of experimental animals with synthetic peptides.
• Assessment of induced antibodies for cross-reactivity with human EGFR, inhibition of ligand binding, receptor activation, and tumor cell growth.

Main Results:

• Novel peptide sequences, including those with KTL and YPLG motifs, were identified that bind to cetuximab and matuzumab.
• Immunization with KTL- and YPLG-containing peptides induced antibodies that cross-react with human EGFR.
• These induced antibodies inhibited natural EGFR ligand binding, ligand-induced receptor activation, and tumor cell growth.

Conclusions:

• Peptide mimotopes can successfully induce anti-EGFR antibodies with significant antitumoral activity.
• These findings suggest a potential new strategy for EGFR-specific cancer immunotherapy.
• The identified peptides may serve as a basis for developing novel therapeutic agents targeting EGFR-driven cancers.